Hyloris Pharmaceuticals SA
ISIN: BE0974363955 | Ticker: HYL
We are a specialty biopharma company committed to bringing innovative, value-added medicines that address the needs of underserved patient populations.
We apply our knowhow and technological innovations to existing pharmaceuticals to unlock their hidden potential and address unmet medical needs. We have built a broad proprietary pipeline of complex value-added products with potential to offer significant advantages over currently available alternatives.
Today, we have two, partnered commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, and Maxigesic® IV, a novel, dual mode-of-action non-opioid analgesic for the treatment of post-operative pain.
Our development strategy of reformulating and repurposing approved pharmaceuticals primarily utilises the 505(b)(2) regulatory pathway in the U.S. and similar pathways in other countries, which are specifically designed for pharmaceutical agents for which the safety and efficacy have already been established.
2012
Served areaWorldwide
HeadquartersBoulevard Patience et Beaujonc 3/1, 4000 Rocourt, Liège – Belgium
28,000,374
IPOJune 29, 2020
Stock exchange(s)Euronext Brussels